404 related articles for article (PubMed ID: 29249304)
1. CAR T-cell therapy in refractory large B-cell lymphoma.
Stirrups R
Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
[No Abstract] [Full Text] [Related]
2. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
3. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
5. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
7. Are all chimeric antigen receptors created equal?
Park JH; Brentjens RJ
J Clin Oncol; 2015 Feb; 33(6):651-3. PubMed ID: 25605860
[No Abstract] [Full Text] [Related]
8. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Oluwole OO; Davila ML
J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
[TBL] [Abstract][Full Text] [Related]
9. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
Frey NV; Porter DL
Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
[TBL] [Abstract][Full Text] [Related]
10. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
11. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
Hardaway JC; Prince E; Arepally A; Katz SC
J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
[No Abstract] [Full Text] [Related]
12. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
13. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
14. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
Gill S; Porter DL
Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
16. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
17. Late Events After CD-19 CAR-T Treatment.
Hossain NM; Nishimura MI
Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
[No Abstract] [Full Text] [Related]
18. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
Stauss HJ; Morris EC
Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
20. DLBCL Responds Well to Anti-CD19 CAR Therapy.
Cancer Discov; 2017 Mar; 7(3):241-242. PubMed ID: 28153859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
